This excerpt taken from the PANC 8-K filed Sep 18, 2008.
ITEM 8.01 OTHER EVENTS.
Panacos Pharmaceuticals, Inc. submitted a series of questions regarding bevirimat, its lead compound in development for HIV, to the U.S. Food and Drug Administration in the third quarter of 2008. The Agencys response included a request to review the efficacy, safety, and pharmacokinetic data from Panacos ongoing multinational study of bevirimats tablets dosed twice daily (Study 204) prior to providing final guidance on the design of the bevirimat extended-duration trial in treatment-experienced patients (Study 205). Therefore, Panacos now expects to begin enrolling patients in Study 205 during the first half of 2009.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.